Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: A before-and-after study

The Lancet Global Health

Volumn 3, Issue 4, 2015, Pages e217-e228

  Li, Renzhong ^a   Ruan, Yunzhou ^a   Sun, Qiang ^b   Wang, Xiexiu ^c   Chen, Mingting ^a   Zhang, Hui ^a   Zhao, Yanlin ^a   Zhao, Jin ^a   Chen, Cheng ^a   Xu, Caihong ^a   Su, Wei ^a   Pang, Yu ^a   Cheng, Jun ^a   Chi, Junying ^a   Wang, Qian ^a   Fu, Yunting ^a   Huan, Shitong ^d   Wang, Lixia ^a   Wang, Yu ^a   Chin, Daniel P ^d  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SHANDONG UNIVERSITY   (China)

^c Chinese Anti Tuberculosis Association   (China)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CHINA; COST; DISEASE CONTROL; ECONOMIC DEVELOPMENT; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HOSPITALIZATION COST; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REIMBURSEMENT; RIFAMPICIN RESISTANT TUBERCULOSIS; SPUTUM SMEAR; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PROGRAM EVALUATION; RETROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; URBAN POPULATION;

ANTITUBERCULAR AGENTS; CHINA; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; URBAN POPULATION;

EID: 84925282361     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(15)70021-5     Document Type: Article

References (41)

1. Multidrug and extensively drug-resistant tuberculosis (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3 2010, WHO, World Health Organization, Geneva.
2. Resolution WHA62.15. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Resolutions and decisions; annexes. 62nd World Health Assembly; Geneva, Switzerland; May 18-22, 2009. WHA62/2009/REC/1 2009, World Health Organization, Geneva, (accessed Feb 27, 2015). http://apps.who.int/gb/ebwha/pdf_files/A62/A62_R15-en.pdf?ua=1.
3. Agenda item 6.1. 134th session World Health Assembly Executive Board. Jan 21, 2014 2014, Global strategy and targets for tuberculosis prevention, care and control after 2015care and control after 2015, World Health Organization, Geneva, (accessed Feb 27, 2015). http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_R4-en.pdf.
4. Falzon D, Jaramillo E, Wares F, et al. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013, 13:690-697.
5. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med 2010, 363:1050-1058.
6. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012, 205(suppl 2):S228-S240.
7. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013, 42:169-179.
8. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable ddrugs; impact on multidrug-resistant TB outcomes. Eur Respir J 2013, 42:156-168.
9. Wang L, Hui Z, Ruan Y, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet 2014, 383:2057-2064.
10. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.
11. He GX, van den Hof S, van der Werf MJ, et al. Inappropriate tuberculosis treatment regimens in Chinese tuberculosis hospitals. Clin Infect Dis 2011, 52:e153-e156.
12. Meng Q, Xu L, Zhang Y, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet 2012, 379:805-814.
13. Ling DI, Zwerling AA, Pai M GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008, 32:1165-1174.
14. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011, 377:1495-1505.
15. Yip WC-M, Hsiao WC, Chen W, Hu S, Ma J, Maynard A Early appraisal of China's huge and complex health-care reform. Lancet 2012, 379:833-842.
16. Pang Y, Xia H, Zhang Z, et al. Multicenter evaluation of Genechip for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2013, 51:1707-1713.
17. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
18. O'Donnell O, van Doorslaer E, Wagstaff A, Lindelow M Analyzing health equity using household survey data: a guide to techniques and their implementation 2008, The World Bank, Washington, DC, (accessed March 4, 2015). https://openknowledge.worldbank.org/handle/10986/6896.
19. Wingfield T, Boccia D, Tovar M, et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med 2014, 11:e1001675.
20. Toczek A, Cox H, du Cros P, Cooke G, Ford N Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2012, 17:299-307.
21. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
22. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
23. Ling DI, Zwerling AA, Pai M Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev Respir Med 2008, 2:583-588.
24. Bwanga F, Hoffner S, Haile M, Joloba ML Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 2009, 9:67.
25. Arentz M, Sorensen B, Horne DJ, Walson JL Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis. PLoS One 2013, 8:e76533.
26. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N Xpert MTB/RIF assay for pulmonary tuberculosis and rifampin resistance in adults. Cochrane Database Syst Rev 2014, 1. CD009593.
27. Bassili A, Fitzpatrick C, Qadeer E, Fatima R, Floyd K, Jaramillo E A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. Am J Trop Med Hyg 2013, 89:271-280.
28. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300.
29. Hanrahan CF, Dorman SE, Erasmus L, Koornhof H, Coetzee G, Golub JE The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study. PLoS One 2012, 7:e49898.
30. Jacobson KR, Theron D, Kendall EA, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013, 56:503-508.
31. Furin J, Bayona J, Becerra M, et al. Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis 2011, 15:1294-1300.
32. Keshavjee S, Gelmanova IY, Pasechnikov AD, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia. Developing programs that address the linkage between poverty and disease. Ann NY Acad Sci 2008, 1136:1-11.
33. Quelapio MI, Mira NR, Orillaza-Chi RB, et al. Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. Int J Tuberc Lung Dis 2010, 14:751-757.
34. Savedoff WD, de Ferranti D, Smith AL, Fan V Political and economic aspects of the transition to universal health coverage. Lancet 2012, 380:924-932.
35. Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a world converging within a generation. Lancet 2013, 382:1898-1955.
36. Gler MT, Guilatco RS, Guray CV, Tupasi TE Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines. Int J Tuberc Lung Dis 2012, 16:1326-1330.
37. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2009, 181:80-86.
38. Ebonwu JI, Tint KS, Ihekweazu C Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011. Int J Tuberc Lung Dis 2013, 17:1043-1048.
39. Jonsson G, Furin J Will molecular diagnosis of drug-resistant tuberculosis improve patient outcome?. Int J Tuberc Lung Dis 2012, 16:4-5.
40. Cavanaugh JS, Kazennyy BY, Nguyen ML, et al. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005. Int J Tuberc Lung Dis 2012, 16:1069-1074.
41. Barter DM, Agboola SO, Murray MB, Barnighausen T Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa-a systematic review. BMC Public Health 2012, 12:980.